• Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL
  • Providers reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of ZUNVEYL
  • Providers reported delayed initiation or discontinuation of concomitant psychotropic medications in 80% of patients receiving ZUNVEYL
  • Providers reported favorable changes in activities of daily living (ADLs) in 71% of patients following initiation of ZUNVEYL
  • Providers reported improvements across sleep-related outcomes in 72% of patients following initiation of ZUNVEYL
  • Providers reported favorable gastrointestinal (GI) tolerability and overall treatment experience in patients receiving ZUNVEYL